Logo

HTG Molecular Diagnostics: Christopher Kiritsy

Jan 28, 2022

HTG Molecular Diagnostics has appointed Christopher Kiritsy to its board. He is currently managing member of private investment and advisory firm Precision Kapital and cofounded and was president and CEO of Arisaph Pharmaceuticals. Before that, Kiritsy was executive VP of corporate development and CFO of Kos Pharmaceuticals.

Breaking News
The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.